Lomtegovimab Biosimilar - Research Grade

Human

Severe acute respiratory syndrome coronavirus 2

>1mg/ml

IgG1 - kappa

CHO Cells

Adintrevimab Biosimilar - Research Grade (ICH5329), Amubarvimab Biosimilar - Research Grade (ICH5342), Bebtelovimab Biosimilar - Research Grade (ICH5377), Beludavimab Biosimilar - Research Grade (ICH5385), Canrivitug Biosimilar - Research Grade (ICH5425), Cilgavimab Biosimilar - Research Grade (ICH5438), Crexavibart Biosimilar - Research Grade (ICH5455), Ensovibep Biosimilar - Research Grade (ICH5528), Etesevimab Biosimilar - Research Grade (ICH5535), Gorivitug Biosimilar - Research Grade (ICH5581), Imdevimab Biosimilar - Research Grade (ICH5598), Masavibart Biosimilar - Research Grade (ICH5672), Nepuvibart Biosimilar - Research Grade (ICH5707), Nisfevitug Biosimilar - Research Grade (ICH5714), Ogalvibart Biosimilar - Research Grade (ICH5725), Pemivibart Biosimilar - Research Grade (ICH5767), Plutavimab Biosimilar - Research Grade (ICH5779), Regdanvimab Biosimilar - Research Grade (ICH5813), Romlusevimab Biosimilar - Research Grade (ICH5834), Simaravibart Biosimilar - Research Grade (ICH5865), Sipavibart Biosimilar - Research Grade (ICH5866), Timcevibart Biosimilar - Research Grade (ICH5923), Tixagevimab Biosimilar - Research Grade (ICH5930), Upanovimab Biosimilar - Research Grade (ICH5958), Vebanvibart Biosimilar - Research Grade (ICH5971)

https://www.imgt.org/mAb-DB/

ICH3002

Blue ice

Neutralizing antibodies against the SARS-CoV-2 surface antigen remain essential tools for infectious-disease and antiviral countermeasure research. Built as an unconjugated, non-therapeutic analog of lomtegovimab, this human IgG1 (kappa) recombinant antibody binds the SARS-CoV-2 antigen and is offered for research use only (RUO). The preparation carries a low endotoxin burden suitable for in vivo work and is generated at scalable milligram-to-gram volumes, supporting laboratories with sustained or high-throughput demand. It functions as a dependable reference and active reagent in viral neutralization assays, in vitro binding screens, and preclinical in vivo challenge models exploring protection and immune mechanisms.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Lomtegovimab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is this research-grade Lomtegovimab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Lomtegovimab biosimilar target?

A: It is a non-therapeutic biosimilar of Lomtegovimab used as a binding and neutralization reagent against Severe acute respiratory syndrome coronavirus 2; for research use only.